The U.S. FDA granted supplemental approval to Calquence (acalabrutinib) for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This approval, part of Project Orbis, where the FDA sought to support oncology-based...